Alzheimer’S Disease Dementia

CHICAGO — Exposure to trauma was tied to increased measures of inflammation and neuronal death for Black women and accelerated brain age indicators regardless of race and ethnicity, researchers reported.

In the third episode of the NSAIDs saga, we focus on COX-2 inhibition! Did the hopes and dreams of selective COX-2 inhibition pan out? What can the rise and fall of VIOXX teach us about physiology?

At the recent Alzheimer's Association International Conference in Amsterdam, an Alzheimer’s Association workgroup proposed revisions to the diagnostic criteria for Alzheimer’s disease.

Early menopause and vascular processes may synergistically contribute to increased risk for Alzheimer’s disease in women, according to a poster presentation at the Alzheimer’s Association International Conference.

NEW ORLEANS — A device designed to improve cerebral blood flow with compression of lower limbs synchronized to the cardiac cycle was tied to improved cognitive performance scores in mild cognitive impairment or Alzheimer’s disease.

CN Diagnostics announced it has received a $15 million program-related investment from GHR Foundation to support and advance the PrecivityAD2 blood test for the detection of Alzheimer’s disease.

Dosing has begun in participants enrolled in a phase 1a clinical trial of OLX-07010, an oral small molecule inhibitor of tau self-association for Alzheimer’s disease, manufacturer Oligomerix announced in a press release.

Both moderate aerobic exercise and stretching and balance activities protected against cognitive decline in older adults with mild cognitive impairment, according to research at the Clinical Trials on Alzheimer’s Disease annual meeting.

A team of Penn State University researchers has been awarded a $1.2 million grant from the NIH to develop a machine learning system for the early detection of Alzheimer’s disease.

Alzheon Inc. reported statistically significant and clinically relevant results in patients with Alzheimer’s disease following 12 months of treatment with the oral investigational therapeutic ALZ-801 in its phase 2 trial.